279 related articles for article (PubMed ID: 24395448)
21. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
23. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Miller DS; Blessing JA; Schilder J; Munkarah A; Lee YC
Gynecol Oncol; 2005 Aug; 98(2):217-21. PubMed ID: 15975641
[TBL] [Abstract][Full Text] [Related]
25. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
[TBL] [Abstract][Full Text] [Related]
26. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA; Filiaci VL; Hensley ML; Huang HQ; Moore KN; Tewari KS; Copeland LJ; Secord AA; Mutch DG; Santin A; Warshal DP; Spirtos NM; DiSilvestro PA; Ioffe OB; Miller DS
J Clin Oncol; 2022 Mar; 40(9):968-977. PubMed ID: 35007153
[TBL] [Abstract][Full Text] [Related]
27. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
[TBL] [Abstract][Full Text] [Related]
29. Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component.
Takamatsu S; Matsumura N; Baba T; Mandai M; Mikami Y; Konishi I
J Obstet Gynaecol Res; 2014 Jan; 40(1):263-7. PubMed ID: 24033661
[TBL] [Abstract][Full Text] [Related]
30. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K
J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534
[TBL] [Abstract][Full Text] [Related]
31. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Hori K; Nishio S; Ushijima K; Kasamatsu Y; Kondo E; Takehara K; Ito K
J Gynecol Oncol; 2021 Jul; 32(4):e64. PubMed ID: 34085798
[TBL] [Abstract][Full Text] [Related]
32. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Miller BE; Blessing JA; Stehman FB; Shahin MS; Yamada SD; Secord AA; Warshal DP; Abulafia O; Richards WE; Van Le L
Gynecol Oncol; 2010 Aug; 118(2):139-44. PubMed ID: 20452658
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Kosmas C; Vorgias G; Tsakonas G; Politis P; Daladimos T; Panagiotidi E; Papachrysanthou T; Moschovis D; Kalinoglou N; Tsavaris N; Karabelis A; Mylonakis N
Br J Cancer; 2011 Sep; 105(7):897-902. PubMed ID: 21847127
[TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of Carboplatin plus Taxane Chemotherapy for Advanced or Recurrent Uterine Serous Carcinoma].
Matsuura T; Otsuka I
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1401-1404. PubMed ID: 27899784
[TBL] [Abstract][Full Text] [Related]
35. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
36. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
38. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
Temkin SM; Hellmann M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Pectasides D; Fountzilas G; Papaxoinis G; Pectasides E; Xiros N; Sykiotis C; Koumarianou A; Psyrri A; Panayiotides J; Economopoulos T
Int J Gynecol Cancer; 2009 May; 19(4):777-81. PubMed ID: 19509587
[TBL] [Abstract][Full Text] [Related]
40. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
